Commodore Capital LP
Commodore Capital LP reported 33 holdings worth US$1.68B as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Commodore Capital LP reported 33 holdings worth US$1.68B as of Jun 30, 2026. Largest: Relay Therapeutics, Inc., Enliven Therapeutics, Inc. and Cogent Biosciences, Inc. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 33
- Value as reported
- US$1.68B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Relay Therapeutics, Inc. | 12M | US$225M | 13.4% |
| Enliven Therapeutics, Inc. | 3.27M | US$166M | 9.9% |
| Cogent Biosciences, Inc. | 3.05M | US$118M | 7.0% |
| Amylyx Pharmaceuticals, Inc. | 5.65M | US$101M | 6.0% |
| Definium Therapeutics, Inc. | 2M | US$94.1M | 5.6% |
| Spyre Therapeutics, Inc. | 847K | US$75.2M | 4.5% |
| Alto Neuroscience, Inc. | 2.72M | US$71.9M | 4.3% |
| Tango Therapeutics, Inc. | 2.25M | US$70.3M | 4.2% |
| Eyepoint, Inc. | 4.6M | US$65.8M | 3.9% |
| Tyra Biosciences, Inc. | 1.88M | US$59.9M | 3.6% |
| Damora Therapeutics, Inc. | 1.94M | US$50.4M | 3.0% |
| Celldex Therapeutics, Inc. | 1.35M | US$50.2M | 3.0% |
| Lb Pharmaceuticals Inc | 1.5M | US$48.7M | 2.9% |
| Assembly Biosciences, Inc. | 1.42M | US$38.9M | 2.3% |
| Editas Medicine, Inc. | 8.89M | US$28.8M | 1.7% |
| Kymera Therapeutics, Inc. | 250K | US$28.7M | 1.7% |
| Perspective Therapeutics, Inc. | 6.34M | US$21.6M | 1.3% |
| Century Therapeutics, Inc. | 8.7M | US$21.3M | 1.3% |
| Zura Bio Limited | 3.25M | US$19.2M | 1.1% |
| Avalo Therapeutics, Inc. | 1.02M | US$18.8M | 1.1% |
| An2 Therapeutics, Inc. | 2.93M | US$14.2M | 0.85% |
| Nuvalent, Inc. | 100K | US$12.3M | 0.74% |
| Sab Biotherapeutics, Inc. | 2.87M | US$11.2M | 0.67% |
| Inhibikase Therapeutics, Inc. | 5.4M | US$11M | 0.65% |
| Relmada Therapeutics, Inc. | 1.43M | US$9.86M | 0.59% |
| Pepgen Inc. | 4.47M | US$8.05M | 0.48% |
| Research Alliance Corporation Iii | 500K | US$5.35M | 0.32% |
| Helix Acquisition Corp. Iii | 500K | US$5.32M | 0.32% |
| Leonabio, Inc. | 464K | US$4.27M | 0.25% |
| Vistagen Therapeutics, Inc. | 2.79M | US$630K | 0.04% |
| Nurix Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Ocular Therapeutix, Inc. | 0 | US$0 | 0.00% |
| Palisade Bio, Inc. | 0 | US$0 | 0.00% |
| Soleno Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Xenon Pharmaceuticals Inc. | 0 | US$0 | 0.00% |
| Corvus Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Erasca, Inc. | 0 | US$0 | 0.00% |
| Karyopharm Therapeutics Inc. | 0 | US$0 | 0.00% |
Source
View original at SEC
Related